1stOncology™: Cancer Intelligence Service – Page 14748 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Rubius Therapeutics to Present at the 36th Annual J.P. Morgan Healthcare Conference

On January 2, 2018 Rubius Therapeutics, a biotechnology company pioneering the creation of a new class of extraordinarily active, ready-to-use and life-changing cellular therapies, reported that David Epstein, executive chairman of Rubius, will provide a corporate presentation at the 36th Annual J.P. Morgan Healthcare Conference (Press release, Rubius Therapeutics, JAN 2, 2018, View Source [SID1234522866]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

The presentation will take place at 7:30 a.m. PST (10:30 a.m. EST) on Monday, January 8, 2018 at the Westin St. Francis Hotel in San Francisco.

Moderna to Provide Corporate and Pipeline Updates and Outline Strategic Priorities at 2018 J.P. Morgan Healthcare Conference

On January 2, 2018 Moderna Therapeutics, a clinical stage biotechnology company that is pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for high unmet medical needs in patients, reported that CEO Stéphane Bancel will provide a detailed strategic update and share new advances in the company’s rapidly expanding pipeline of mRNA development candidates, at this year’s 36th annual J.P. Morgan Healthcare Conference (Press release, Moderna Therapeutics, JAN 2, 2018, View Source [SID1234522865]).

Mr. Bancel’s presentation will take place on Monday, January 8, 2018 at 2:30 p.m. PT in Elizabethan Room C/D at The Westin St. Francis Hotel in San Francisco.

Ophthotech Corporation to Present at the 36th Annual J.P. Morgan Healthcare Conference

On January 2, 2018 Ophthotech Corporation (NASDAQ: OPHT) reported that Glenn P. Sblendorio, Chief Executive Officer and President, will present an overview of the Company at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, January 11, 2018 at 8:00 a.m. Pacific Time (11:00 a.m. Eastern Time) (Press release, Ophthotech, JAN 2, 2018, View Source [SID1234522860]).

Investors and the general public are invited to listen to a live webcast of the presentation at www.ophthotech.com. Please connect to Ophthotech’s website several minutes prior to the start of the presentation to ensure adequate time for any software download that may be necessary. A replay will be available for 14 days following the presentation.

Supernus to Present at the 2018 J.P. Morgan Healthcare Conference

On January 2, 2018 Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, reported that the Company’s management will present an overview and update for the Company, and host investor meetings at the 36th Annual J.P. Morgan Healthcare Conference (Press release, Supernus, FEB 2, 2018, View Source [SID1234522857]).

Date: Wednesday, January 10, 2018

Time: 12:00 p.m. PT / 3:00 p.m. ET
Place: Westin St. Francis Hotel, San Francisco, CA

Investors interested in arranging a meeting with the Company’s management during these conferences should contact the conference coordinator.

A live webcast of the presentation can be accessed by visiting ‘Events & Presentations’ in the Investors Section on the Company’s website at www.supernus.com. An archived replay of this webcast will be available for 60 days subsequent to the Company’s presentation.

Tetraphase Pharmaceuticals Appoints Larry Tsai, M.D. to Chief Medical Officer

On January 2, 2018 Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, reported the promotion of Larry Tsai, M.D., Vice President, Clinical Development, to Chief Medical Officer (CMO) (Press release, Tetraphase, JAN 2, 2018, View Source [SID1234522838]).

"Larry has provided significant expertise to the clinical team throughout the IGNITE phase 3 program for eravacycline, our lead antibiotic candidate, as well as in the early clinical development of the Company’s pipeline programs," said Guy Macdonald, President and Chief Executive Officer of Tetraphase. "We are delighted to welcome him to the management team. His leadership of the clinical team will be important as we move forward with the new drug application (NDA) regulatory process for IV eravacycline in complicated intra-abdominal infections (cIAI) and as we await the topline data readout for our IGNITE3 phase 3 trial in complicated urinary tract infections (cUTI). We remain on track to report IGNITE3 topline data this quarter."

"I am excited to be taking on this leadership role at Tetraphase," said Dr. Tsai. "I look forward to continuing to work with the rest of management to realize the full potential of eravacycline as a treatment option for serious, and often life-threatening, MDR gram-negative infections."

Dr. Tsai joined the Company in 2014 as senior medical director and became vice president, clinical development in 2015. He has nearly 20 years of experience in healthcare and clinical development. Prior to joining Tetraphase, he was vice president of research and development, in addition to medical director, at Aeris Therapeutics. Dr. Tsai is also a practicing physician at Brigham and Women’s Hospital in Boston, Massachusetts and a part-time instructor in medicine at Harvard Medical School.

Dr. Tsai holds a Bachelor of Science in Biology from Stanford University and an M.D. from the Health Sciences and Technology Program at Harvard Medical School. He is board certified in critical care medicine, internal medicine and pulmonary disease.